GLONGHUI, May 16 | Bojian and Ionis Pharmaceuticals said on Thursday that they will stop developing an experimental therapy (ALS) to treat amyotrophic lateral sclerosis (ALS). In an early to mid-term study, the patient's condition did not improve. ALS, commonly known as Lugaray's disease, is a rare and fatal neurodegenerative disease that affects the autonomous control of hands and feet and causes breathing difficulties. The two companies' drug BIIB105 did not succeed in significantly reducing neurodegeneration or improving functional indicators such as breathing in patients. In the US and Europe, around 60,000 people are affected by ALS.